|
|
Vaccine Detail
|
Modified Vaccinia Virus Ankara Vaccine Expressing p53 |
| Vaccine Information |
- Vaccine Name: Modified Vaccinia Virus Ankara Vaccine Expressing p53
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007643
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: p53
- human TP53 (P53)
gene engineering:
- Type: Recombinant protein preparation
- Description: (Song et al., 2011)
- Detailed Gene Information: Click Here.
- Description: A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the wild-type form of the tumor protein p53 (wt p53), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with MVA vaccine expressing p53, the expressed p53 may stimulate the host immune system to mount a p53-specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing p53, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain and is incapable of virion assembly. The p53 gene, a tumor suppressor gene, is mutated in many cancer cell types. (NCIT_C116868).
|
| Host Response |
|
|
| References |
NCIT_C116868: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116868]
Song et al., 2011: Song GY, Srivastava T, Ishizaki H, Lacey SF, Diamond DJ, Ellenhorn JD. Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion. Cancer investigation. 2011; 29(8); 501-510. [PubMed: 21843052].
|
|
